

The role of alpha-synuclein misfolding in Parkinson's disease.

<https://www.neurodegenerationresearch.eu/survey/the-role-of-alpha-synuclein-misfolding-in-parkinsons-disease/>

Name of Fellow

Dr Sonia Gandhi

Institution

Funder

Wellcome Trust

Contact information of fellow

Country

United Kingdom

Title of project/programme

The role of alpha-synuclein misfolding in Parkinson's disease.

Source of funding information

Wellcome Trust

Total sum awarded (Euro)

€ 877,661

Start date of award

01/10/13

Total duration of award in years

5.0

The project/programme is most relevant to:

Parkinson's disease & PD-related disorders

Keywords

Cognitive impairment | Dementia | Neurodegen | Neurodegen | Parkinson

Research Abstract

Aim To determine how oligomerisation of alpha-synuclein induces neuronal toxicity in Parkinsons disease. Objective 1: Molecular characterization of oligomerisation The key

intermediate goals: (a) to apply biophysical methods (single molecule TCCD and single molecule FRET) to characterize and isolate the different alpha-synuclein species (monomers, oligomers, fibrils) generated during aggregation of fluophore labeled alpha-synuclein (b) to test the effect of alpha-synuclein mutations and alpha-synuclein phosphorylation on aggregation Objective 2: Investigation of pathogenesis of oligomerisation in disease models The key intermediate goals are: (a) to characterize a range of mammalian stem cell derived neuronal models expressing different levels of alpha-synuclein. (b) to test the effect of different alpha-synuclein species on uptake and intracellular aggregation in disease models. (c) to investigate the effect of different alpha-synuclein species on cellular processes in particular mitochondrial function, calcium signaling and cell death. (d) to study how endogenous alpha-synuclein may aggregate in neuronal models using recombinant nanobodies that specifically recognize different alpha-synuclein species. Objective 3: Validating targets for therapy Any compound proven to inhibit formation of the toxic species will be tested in cell models to confirm whether it also abrogates toxicity. This represents the translation from in vitro modelling to rational disease modifying drug design in Parkinson's disease.

Types:

Fellowships

Member States:

United Kingdom

Diseases:

Parkinson's disease & PD-related disorders

Years:

2016

Database Categories:

N/A

Database Tags:

N/A